BioCentury
ARTICLE | Clinical News

Endotoxin Activity Assay regulatory update

April 7, 2003 7:00 AM UTC

The FDA said SDI's EAA severe sepsis risk test qualifies for marketing clearance under the de novo process, which is a regulatory provision for new medical devices. SDI said the test now needs to be e...